- Home
- HBT vs PHAT Comparison
HBT vs PHAT Comparison
Compare HBT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- PHAT
- Stock Information
- Founded
- HBT 1920
- PHAT 2018
- Country
- HBT United States
- PHAT United States
- Employees
- HBT N/A
- PHAT N/A
- Industry
- HBT Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- PHAT Health Care
- Exchange
- HBT Nasdaq
- PHAT Nasdaq
- Market Cap
- HBT 812.0M
- PHAT 942.6M
- IPO Year
- HBT 2019
- PHAT 2019
- Fundamental
- Price
- HBT $23.74
- PHAT $14.61
- Analyst Decision
- HBT Buy
- PHAT Strong Buy
- Analyst Count
- HBT 5
- PHAT 5
- Target Price
- HBT $28.63
- PHAT $17.60
- AVG Volume (30 Days)
- HBT 32.8K
- PHAT 977.8K
- Earning Date
- HBT 10-20-2025
- PHAT 10-30-2025
- Dividend Yield
- HBT 3.52%
- PHAT N/A
- EPS Growth
- HBT 12.74
- PHAT N/A
- EPS
- HBT 2.48
- PHAT N/A
- Revenue
- HBT $233,255,000.00
- PHAT $147,190,000.00
- Revenue This Year
- HBT $9.02
- PHAT $218.38
- Revenue Next Year
- HBT $32.67
- PHAT $87.14
- P/E Ratio
- HBT $9.61
- PHAT N/A
- Revenue Growth
- HBT 6.87
- PHAT 460.30
- 52 Week Low
- HBT $19.46
- PHAT $2.21
- 52 Week High
- HBT $27.02
- PHAT $16.08
- Technical
- Relative Strength Index (RSI)
- HBT 41.94
- PHAT 63.36
- Support Level
- HBT $23.24
- PHAT $14.07
- Resistance Level
- HBT $24.11
- PHAT $15.28
- Average True Range (ATR)
- HBT 0.61
- PHAT 1.05
- MACD
- HBT -0.00
- PHAT 0.06
- Stochastic Oscillator
- HBT 23.76
- PHAT 59.09
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.